Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other financing activities (2016 - 2022)

Historic Other financing activities for UroGen Pharma (URGN) over the last 6 years, with Q3 2022 value amounting to $16000.0.

  • UroGen Pharma's Other financing activities fell 8620.69% to $16000.0 in Q3 2022 from the same period last year, while for Jun 2023 it was $16000.0, marking a year-over-year decrease of 9422.38%. This contributed to the annual value of $160000.0 for FY2022, which is 1111.11% up from last year.
  • As of Q3 2022, UroGen Pharma's Other financing activities stood at $16000.0, which was down 8620.69% from $55000.0 recorded in Q2 2022.
  • In the past 5 years, UroGen Pharma's Other financing activities registered a high of $202.7 million during Q3 2018, and its lowest value of $11000.0 during Q4 2020.
  • For the 4-year period, UroGen Pharma's Other financing activities averaged around $52.7 million, with its median value being $89000.0 (2022).
  • Within the past 5 years, the most significant YoY rise in UroGen Pharma's Other financing activities was 40000.0% (2022), while the steepest drop was 8620.69% (2022).
  • Over the past 4 years, UroGen Pharma's Other financing activities (Quarter) stood at $202.7 million in 2018, then crashed by 99.99% to $11000.0 in 2020, then skyrocketed by 54.55% to $17000.0 in 2021, then decreased by 5.88% to $16000.0 in 2022.
  • Its Other financing activities stands at $16000.0 for Q3 2022, versus $55000.0 for Q2 2022 and $89000.0 for Q1 2022.